Comparisons of unmanipulated haploidentical donor, unrelated cord blood donor and matched unrelated donor hematopoietic stem cell transplantation in pediatric acquired severe aplastic anemia: a single center study

References

• Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643–1656.
   PubMed Web of Science ®Google Scholar
• Dufour C, Paillon M, Carrano E, et al. Outcome of aplastic anaemia in children: a study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015;169(4):565–573.
   PubMed Web of Science ®Google Scholar
• Dufour C, Veys P, Bhatnagar N, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia: a study on behalf of the UK paediatric BMT working party, paediatric diseases working party and severe aplastic anaemia working party of EBMT. Br J Haematol. 2015b;171(4):585–594. 2015
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. Alternative donor transplants for severe aplastic anemia. Hematol Am Soc Hematol Educ Program. 2018;2018(1):467–473.
   PubMedGoogle Scholar
• Prasad VK, Kurtzberg J. Umbilical cord blood transplantation for non-malignant diseases. Bone Marrow Transplant. 2009;44(10):643–651.
   PubMed Web of Science ®Google Scholar
• Xu LP, Zhang XH, Wang FR, et al. Haploidentical transplantation for pediatric patients with acquired severe aplastic anemia. Bone Marrow Transplant. 2017;52(3):381–387.
   PubMed Web of Science ®Google Scholar
• Xu LP, Jin S, Wang SQ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol. 2017;10:1–10.
   PubMed Web of Science ®Google Scholar
• Lu Y, Sun R, Zhao Y, et al. Unmanipulated haploidentical hematopoietic stem cell transplantation achieved outcomes comparable with matched unrelated donor transplantation in young acquired severe aplastic anemia. Biol Blood Marrow Transplant. 2018;24(9):1881–1887.
   PubMed Web of Science ®Google Scholar
• De Latour RP, Purtill D, Ruggeri A, et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by Eurocord and the aplastic anemia working party of the European group for blood and marrow transplant. Biol Blood Marrow Transplant. 2011;17(1):78–85.
   PubMed Web of Science ®Google Scholar
• Yoshimi A, Kojima S, Taniguchi S, et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant. 2008;14(9):1057–1063.
   PubMed Web of Science ®Google Scholar
• Kudo K, Muramatsu H, Narita A, et al. Unrelated cord blood transplantation in aplastic anemia: is anti-thymocyte globulin indispensable for conditioning? Bone Marrow Transplant. 2017;52(12):1659–1661.
   PubMed Web of Science ®Google Scholar
• Latour RD, Chevret S, Jubert C, et al. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. Blood. 2018;132(7):750–754.
   PubMed Web of Science ®Google Scholar
• Yoshida N, Kojima S. Updated guidelines for the treatment of acquired aplastic anemia in children. Curr Oncol Rep. 2018;20(9):67.
   PubMed Web of Science ®Google Scholar
• Sieff CA. Introduction to acquired and inherited bone marrow failure. Hematol Oncol Clin North Am. 2018;32(4):569–580.
   PubMed Web of Science ®Google Scholar
• Munoz J, Shah N, Rezvani K, et al. Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med. 2014;3(12):1435–1443.
   PubMed Web of Science ®Google Scholar
• Shaw A, Passweg JR, De La Fuente J, et al. Relapse of aplastic anemia with majority donor chimerism (donor-type aplasia) occurring late after bone marrow transplantation. Biol Blood Marrow Transplant. 2020;26(3):480–485.
   PubMed Web of Science ®Google Scholar
• Holtan SG, Defor TE, Lazaryan A, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125(8):1333–1338.
   PubMed Web of Science ®Google Scholar
• Lu D, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8):3065–3073.
   PubMed Web of Science ®Google Scholar
• Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1.
   PubMed Web of Science ®Google Scholar
• Clark JR, Scott SD, Jack AL, et al. Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (hsct): technical recommendations for the use of Short Tandem Repeat (STR) based techniques, on behalf of the. Br J Haematol. 2015;168(1):26–37.
   PubMed Web of Science ®Google Scholar
• Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207.
   PubMed Web of Science ®Google Scholar
• Bing H. Comparison of frontline treatment with intensive immunosuppression therapy and HLA-haploidentical hematopoietic stem cell transplantation for young patients with severe aplastic anemia – a meta analysis. Leuk Res. 2019;88:106266.
   PubMed Web of Science ®Google Scholar
• Cheng YF, Xu ZL, Zhang YY, et al. First-line choice for severe aplastic anemia in children: transplantation from a haploidentical donor vs immunosuppressive therapy. Clin Transplant. 2018;32(2):e13179.
   Web of Science ®Google Scholar
• Yamei W, Rongmu L, Yongbin C, et al. Improved outcome of haploidentical transplantation in severe aplastic anemia using reduced-intensity fludarabine-based conditioning. Oncotarget. 2017;8(48):83817–83830.
   PubMedGoogle Scholar
• Xu LP, Wang SQ, Wu DP, et al. Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. Br J Haematol. 2016;175(2):265–274.
   PubMed Web of Science ®Google Scholar
• Kuwatsuka Y, Kanda J, Yamazaki H, et al. Transplantation a comparison of outcomes for cord blood transplantation and unrelated bone marrow transplantation in adult aplastic anemia. Biol Blood Marrow Transplant. 2016;22(10):1836–1843. 2016
   PubMed Web of Science ®Google Scholar
• Lee S, Yahng S, Cho B, et al. Impact of pretransplant red cell transfusion on outcome after allogeneic stem cell transplantation in adult patients with severe aplastic anemia. Bone Marrow Transplant. 2016;51(10):1323–1329.
   PubMed Web of Science ®Google Scholar
• Arcuri LJ, Nabhan SK, Cunha R, et al. Impact of CD34 cell dose and conditioning regimen on outcomes after haploidentical donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for relapsed/refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2020;26(12):2311–2317.
   PubMed Web of Science ®Google Scholar
• Prata PH, Eikema D-J, Afansyev B, et al. Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT severe aplastic anemia working party. Bone Marrow Transplant. 2020;55(6):1050–1058.
   PubMed Web of Science ®Google Scholar
• DeZern AE, Zahurak ML, Symons HJ, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4(8):1770–1779.
   PubMed Web of Science ®Google Scholar
• Esteves I, Bon C, Pasquini R, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant. 2015;50(5):685–689.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Socie’ G, Lanino E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the ebmt-saa working party. Haematologica. 2010;95(6):976–982.
   PubMed Web of Science ®Google Scholar
• Rocha V, Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol. 2009;147(2):262–274.
   PubMed Web of Science ®Google Scholar
• Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611–1618.
   PubMed Web of Science ®Google Scholar
• Dulley FL, Vigorito AC, Aranha FJP, et al. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transplant. 2004;33(1):9–13.
   PubMed Web of Science ®Google Scholar
• Onishi Y, Nasu K, Onodera K, et al. Reduced-intensity conditioning without antithymocyte globulin in adult patients with severe aplastic anemia. Biol Blood Marrow Transplant. 2019;25(2):e55–e59.
   PubMedGoogle Scholar
• ElGohary G, El Fakih R, Latour R D, et al. Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT). Bone Marrow Transplant. 2020;55:1906–1917.
   PubMedGoogle Scholar